Hong Kong Exchanges and Clearing Limited and The Stock
Exchange of Hong Kong Limited take no responsibility for the
contents of this announcement, make no representation as to
its accuracy or completeness and expressly disclaim any
liability whatsoever for any loss howsoever arising from or
in reliance upon the
whole or any part of the contents of this announcement.
SBI HOLDINGS, INC.
(Incorporated in Japan with limited liability)
(Stock code: 6488)
OVERSEAS REGULATORY ANNOUNCEMENT
This announcement is made pursuant to Rule 13.09(2) of the
Rules Governing the Listing of Securities on The Stock
Exchange of Hong Kong Limited.
Please refer to the attached copy of the Announcement.
On behalf of the Board SBI Holdings, Inc. Yoshitaka Kitao
Chief Executive Officer
Japan, 30 March 2012
As of the date of this announcement, the executive Directors
are Mr Yoshitaka Kitao, Mr Taro Izuchi, Mr Takashi Nakagawa,
Mr Kenji Hirai, Mr Tomoya Asakura, Mr Takashi Okita, Mr
Noriaki Maruyama, Mr Shumpei Morita, Mr Shinji Yamauchi, Mr
Makoto Miyazaki, Mr Yoshimi Takahashi and Mr Masaki
Takayanagi, the non-executive Directors are Mr Yasutaro
Sawada, Mr Hiroyoshi Kido, Mr Noriyoshi Kimura and Mr Hiroshi
Tasaka and the independent non-executive Directors are Mr
Masaki Yoshida, Mr Kiyoshi Nagano, Mr Keiji Watanabe, Mr
Takeshi Natsuno and Mr Akihiro Tamaki.
March 30, 2012
Notice on Partial Transfer of Subsidiary Shares and the
Resulting Extraordinary Income
SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488)
SBI Holdings, Inc. ("SBIH") hereby announces that it will
transfer some of the shares its subsidiary holds in
consolidated subsidiary SBI ALApromo Co, Ltd. (the company
name is to be changed to SBI Pharmaceuticals Co., Ltd. on
April 1, 2012; head office: Minato-ku, Tokyo; Representative
Director and CEO: Yoshitaka Kitao; "SBI ALApromo"). The
shares will be transferred to multiple third parties. SBIH is
expected to book an extraordinary income as a result of this
1. Reasons for the transfer
SBI ALApromo, which obtained First-class Marketing
Authorization in February 2012, is actively engaged in
research and development of medicines, cosmetics and health
foods using 5-aminolevulinic acid (ALA)* as a pharmaceutical
company. As SBI ALApromo plans to accelerate development of
new drugs utilizing ALA, the proceeds from this transfer will
be allocated primarily for prior investments in the business.
The transferees of the shares were determined in
consideration of their ability to contribute to future growth
of ALA businesses in various aspects.
2. Status of shares held by the SBI Group before and after
the share transfer
(1) Holding ratio before the transfer 79.15% (2) Holding
ratio after the transfer 73.32%
3. Future outlook
As a result of this transfer, consolidated extraordinary
income of approximately 4.2 billion yen is expected to be
recorded for the fiscal year ending March 2012.
* About 5-aminolevulinic acid (ALA):
An amino acid created in mitochondria. It is an important
substance that serves as protein material related to energy
production in the form of hemes and cytochromes, and its
productivity is known to decrease with age. ALA is contained
in shochu distillation remnants, red wine and food such as
radish sprouts. It is also known as a material forming
chloroplasts in plants.